Efficacy and safety of oral immunotherapy with short ragweed extract.
BACKGROUND
Oral immunotherapy, if proven safe and effective, could be an alternative to subcutaneous immunotherapy.


OBJECTIVE
This pilot study investigated the clinic and immunologic effects of ragweed immunotherapy using a new microencapsulated, pH-sensitive, oral delivery system.


METHODS
A double-blind, placebo-controlled trial was conducted in 23 patients with allergic rhinitis to short ragweed. Following a baseline nasal challenge with ragweed allergen, oral immunotherapy with encapsulated short ragweed extract or placebo was administered once daily, 6 days/week. Dosed began at 3 micrograms Amb a 1 per day and were increased by 3 micrograms every three days as tolerated, to a maximum daily maintenance dose of 24 micrograms. A nasal challenge was repeated 6 weeks, later, followed by the continuation of maintenance therapy through the natural ragweed season. Daily allergy symptoms and relief medication usage was recorded. A final nasal challenge was performed at the end of the natural season. Short ragweed-specific serum IgE, IgG, and IgG4 antibody levels were measured every 2 weeks during the study.


RESULTS
Maximum tolerated doses ranged from 6 to 24 micrograms Amb a 1 per day (74% reached 24 micrograms). Adverse events were not serious or different between the active and placebo groups. The active group showed increased in short ragweed-specific serum IgG and IgG4 antibody levels. Symptom scores during the natural season were numerically but not statistically lower in the active treatment group. This group also experienced a greater reduction from baseline in nasal reactivity as assessed by nasal challenge.


CONCLUSIONS
These pilot data suggest that the encapsulated, pH-sensitive oral immunotherapy delivery system was safe, induced a brisk serologic response, and attenuated the symptomatic response to both experimental and environmental ragweed exposure.
Van Deusen
M A
MA
Children's Hospital of Pittsburgh Pennsylvania, USA.
Angelini
B L
BL
Cordoro
K M
KM
Seiler
B A
BA
Wood
L
L
Skoner
D P
DP
D000284:Administration, Oral; D000328:Adult; D000485:Allergens; D052179:Antigens, Plant; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy / Q000379:methods* / Q000592:standards; D009299:Nasal Provocation Tests; D010940:Plant Proteins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D011058:Pollen / Q000276:immunology; D012129:Respiratory Function Tests; D013223:Statistics as Topic
D000485:Allergens; C028564:Amb a III protein, Ambrosia artemisiifolia; D052179:Antigens, Plant; D007074:Immunoglobulin G; D010940:Plant Proteins; D007073:Immunoglobulin E